Similar articles

• Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

  Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Rivkin SE, et al. J Clin Oncol. 1994 Oct;12(10):2078-85. doi: 10.1200/JCO.1994.12.10.2078. J Clin Oncol. 1994. PMID: 7931477 Clinical Trial.
• Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.

  Hartman AR, Fleming GF, Dillon JJ. Hartman AR, et al. Clin Breast Cancer. 2001 Jul;2(2):138-43; discussion 144. doi: 10.3816/CBC.2001.n.018. Clin Breast Cancer. 2001. PMID: 11899785
• Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

  Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Pagani O, et al. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. Breast Cancer Res Treat. 2009. PMID: 18953651 Free PMC article. Clinical Trial.
• A cost-effectiveness analysis of axillary node dissection in postmenopausal woman with estrogen receptor-positive breast cancer and clinically negative axillary nodes.

  Copeland EM 3rd. Copeland EM 3rd. Surgery. 1999 Nov;126(5):987-8. doi: 10.1016/s0039-6060(99)70046-2. Surgery. 1999. PMID: 10568204 Review. No abstract available.
• [Adjuvant chemotherapy of early stage breast cancer].

  Boér K. Boér K. Orv Hetil. 2010 Feb 28;151(9):344-53. doi: 10.1556/OH.2010.28824. Orv Hetil. 2010. PMID: 20159750 Review. Hungarian.